Natera Reports Outcomes From Study of MRD Test for Soft Tissue and Bone Sarcomas

Yahoo FinanceMay 6 10:24 ET

Craig-Hallum Maintains Natera(NTRA.US) With Buy Rating

Moomoo NewsMay 6 03:33 ET · Ratings

Analysts Offer Insights on Healthcare Companies: CVRx (CVRX), Envista Holdings (NVST) and Natera (NTRA)

TipRanksMay 5 09:20 ET · Ratings

Natera Announces Results of Signatera Study

TipRanksMay 5 07:15 ET

Express News | Natera's Signatera Shows 93% Sensitivity In Leiomyosarcoma, Most Common Sarcoma Subtype In Study

BenzingaMay 5 07:06 ET

Largest Sarcoma Study to Date With CtDNA Analysis Demonstrates Excellent Performance for Signatera

NateraMay 5 00:00 ET